Drug Trial Radar · NCT06905327
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Mar 8, 2023
Primary completion
Sep 25, 2024
Study completion Jul 1, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study including Part A single ascending dose (SAD) in healthy subjects and Part B single dose in subjects with mild hypertension.
Conditions
- Mild Hypertension
Interventions
QCZ484Drug
doses of 50, 150, 300 or 600 mg via subcutaneous injection
PlaceboDrug
via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events (AEs)Time frame: Part A: up to 12 weeks post dose. Part B: up to 8 weeks post dose.
- Number of participants with abnormalities in any laboratory parameterTime frame: Part A: up to 12 weeks post dose. Part B: up to 8 weeks post dose
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
Herston, Queensland, Australia
Novartis Investigative Site
Morayfield, Queensland, Australia
Novartis Investigative Site
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.